Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effectiveness and safety of
cyclobenzaprine hydrochloride extended release (Amrix 15mg/day) for the prophylaxis of
chronic migraine compared to a placebo medication. A second objective, is to find out whether
there is an improvement in quality of sleep and self-reported depression in patients taking
Amrix 15mg daily. The hypothesis is that the number of migraine days per month of patients
treated with Amrix 15mg daily will be significantly lower than those patients treated with
placebo.